Celltrion increases its stake in British ADC developer Iksuda

The leading S.Korean drugmaker and new growth fund secured total of 47% stake of the UK company

Celltrion's headquarters in Songdo, Korea
Celltrion's headquarters in Songdo, Korea
Jae-Young Han 1
Jan 25, 2023 (Gmt+09:00) jyhan@hankyung.com
Bio & Pharma

Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.

According to Celltrion on Wednesday, it acquired additional stakes in Iksuda in two ways, including Celltrion's recent direct investment and Mirae Asset Celltrion Growth Fund, in which the company took part jointly with Mirae Asset Group.

Celltrion, who had previously been looking for growth engines in the anti-cancer area, signed an agreement with Mirae Asset Group in Jun. 2021 to participate in the Iksuda Series A funding.

The Iksuda Series A fund, led by the two companies, invested a total of 53 billion won ($47 million), and secured a total of 47% in the British company.

Iksuda is a company that develops the next-generation ADC for incurable cancer drugs. ADC is an anti-cancer technology that has recently received attention by specifically attacking cancer cells by connecting antibody drugs and chemical anti-cancer drugs (payloads).

Write to Jae-Young Han at jyhan@hankyung.com

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion's Yuflyma Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosimilar of Humira (active ingredient: adalimumab), an autoimmune disease treatment developed by AbbVie of the US.Currently, the So

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) has been approved in more than 100 countries ten years after its first approval.Remsima is a TNF-alpha inhibitor that is used to

Celltrion, Mirae to take largest stake in UK biotech firm

Celltrion, Mirae to take largest stake in UK biotech firm

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda Therapeutics, a UK-based developer of antibody-drug conjugates (ADCs), for $47 million.Celltrion expects the investment to expand its cancer drug